🇺🇸 FDA
Patent

US 12329824

Muscle targeting complexes and uses thereof for treating dystrophinopathies

granted A61KA61K2039/505A61K2039/545

Quick answer

US patent 12329824 (Muscle targeting complexes and uses thereof for treating dystrophinopathies) held by Dyne Therapeutics, Inc. expires Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Dyne Therapeutics, Inc.
Grant date
Tue Jun 17 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jun 12 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
30
CPC classes
A61K, A61K2039/505, A61K2039/545, A61K38/00, A61K47/6807